SSRG International Journal of Pharmacy and Biomedical Engineering
ISSN: 2394 – 2576 / https://doi.org/10.14445/24547484/IJPBE-V10I2P101

Volume 10 Issue 2, 1-6, May-Aug 2023

Original Article

Drug Delivery and Nanomedicine: Exploring CRM's Potential in Patient-Centric Approaches

Sharda Kumari

Systems Architect, CA, USA

Received: 01 March 2023 Revised: 10 April 2023 Accepted: 22 April 2023 Published: 05 May 2023

Abstract *- This research paper investigates the potential of customer relationship management (CRM) systems in enhancing patient-centric approaches in drug delivery and nanomedicine. With the growing significance of nanotechnology in targeted drug delivery and reduced side effects, understanding how CRM can improve patient care and outcomes is crucial. The paper discusses the role of CRM in healthcare, focusing on managing patient data, communication, and overall patient experience. Personalized healthcare is emphasized, with CRM facilitating streamlined interactions and increased patient engagement. The research examines CRM applications in drug delivery and nanomedicine, demonstrating how CRM can help monitor patient adherence, manage side effects, and adjust drug dosages. It also highlights CRM-enabled personalized drug delivery through tracking patient responses and identifying potential drug interactions. Challenges and opportunities related to CRM integration are addressed, including data privacy, security, and technological adaptation. Potential benefits, such as improved patient outcomes and cost savings, are also discussed. The paper underscores the potential of CRM in enhancing patient-centric approaches in drug delivery and nanomedicine and emphasizes the need for continued research. Future directions, such as integrating artificial intelligence into CRM systems, are suggested to enhance patient care further and optimize drug delivery processes.*

Keywords *- Nanomedicine, Customer relationship management, Digital innovation, Drug delivery, Pharmacy*

1. Introduction

Nanotechnology has emerged as a revolutionary force in modern healthcare, offering innovative solutions for targeted drug delivery, improved drug solubility, and reduced side effects [1][4]. Concurrently, the focus of healthcare is shifting towards patient-centric approaches, where the individual patient needs and preferences are prioritized [2]. Integrating customer relationship management (CRM) systems into drug delivery and nanomedicine can enhance these patient-centric approaches by streamlining patient interactions, providing real-time data access, and promoting patient engagement [2][20].

CRM systems have been widely used in various industries to manage customer data, improve communication, and enhance customer satisfaction [2]. In healthcare, CRM can facilitate personalized patient care by enabling healthcare providers to understand patient histories, preferences better, and needs [15][16]. This personalized approach can potentially improve patient outcomes and reduce healthcare costs [2][20]. Recent advances in nanomedicine have led to the development of novel drug delivery systems, such as liposomes, polymeric nanoparticles, and nanostructured lipid carriers [1][7][9][26]. These systems can enhance drug efficacy and minimize adverse effects by delivering drugs directly to targeted tissues and cells [1][10]. Integrating CRM systems into drug delivery and nanomedicine can further optimize these processes by providing personalized drug delivery based on individual patient needs [2][20]. For example, CRM systems can help monitor patient adherence to treatment plans, manage side effects, and adjust drug dosages as needed [20][21]. In addition, CRM systems can facilitate personalized drug delivery by tracking patient responses, ensuring optimal drug concentrations, and identifying potential drug interactions [2][20]. This personalized approach enhances patient outcomes and contributes to cost savings and more efficient healthcare delivery [2][20].

Integrating CRM systems into drug delivery and nanomedicine presents several challenges, including data privacy, security, and technological adaptation [2][31]. Healthcare professionals must adapt to new technologies and maintain the interoperability of systems to ensure seamless data flow and communication [2][31]. Despite these challenges, the potential benefits of CRM integration, such as improved patient outcomes and cost savings, warrant continued research and development [2][20][31]. Future directions in this field include integrating artificial intelligence (AI) and machine learning into CRM systems to enhance patient care further and optimize drug delivery processes [32]. AI-driven CRM systems can analyze large datasets, identify patterns, and generate personalized treatment plans based on

individual patient needs and preferences [32]. This integration can lead to even more precise drug delivery, improved patient outcomes, and a more efficient healthcare system. CRM systems have the potential to significantly impact drug delivery and nanomedicine by enhancing patient-centric approaches. Integrating CRM into these fields can improve patient outcomes, reduce healthcare costs, and streamline processes. Continued research and development, including the incorporation of AI and machine learning, will further advance the potential of CRM in drug delivery and nanomedicine.

3. Literature Review

The significance of drug delivery and nanomedicine in modern healthcare cannot be overstated, as these fields have revolutionized targeted drug delivery systems, improved drug solubility, and reduced side effects [4][13][34]. Patient-centric approaches are essential to address individual patient needs and preferences, and the potential of customer relationship management (CRM) systems in enhancing these approaches is a topic of growing interest [2][25].

CRM plays a vital role in healthcare by managing patient data, improving communication, and enhancing the overall patient experience [2][25]. Personalized healthcare has become increasingly important, and CRM systems can facilitate this by streamlining patient interactions, providing real-time data access, and promoting patient engagement [2][20]. CRM has several applications in drug delivery and nanomedicine, such as monitoring patient adherence to treatment plans, managing side effects, and adjusting drug dosages as needed [20][25]. Furthermore, CRM systems can facilitate personalized drug delivery by tracking patient responses, ensuring optimal drug concentrations, and identifying potential drug interactions [20].

Integrating CRM into drug delivery and nanomedicine presents challenges and opportunities. Issues related to data privacy, security, and the need for healthcare professionals to adapt to new technologies must be addressed [26][33]. Despite these challenges, potential opportunities, such as improved patient outcomes, cost savings, and streamlined processes, may result from successful CRM implementation in these fields [2][20]. The potential of CRM in enhancing patient-centric approaches in drug delivery and nanomedicine is significant, and continued research and development are required to fully realize the benefits of CRM in these fields [2][20][25]. Future directions may include integrating artificial intelligence and machine learning into CRM systems to enhance patient care further and optimize drug delivery processes [5][18].

4. Drug Delivery and Nanomedicine

Drug delivery and nanomedicine have emerged as vital aspects of modern healthcare, offering significant advancements and benefits to both patients and medical professionals. As the fields continue to evolve, their role in shaping the future of medicine and healthcare is becoming increasingly apparent.

At the core of drug delivery and nanomedicine is nanotechnology, which has revolutionized the way drugs are administered, absorbed, and metabolized in the human body. Targeted drug delivery systems can be developed by employing nanoparticles to ensure the medication reaches the specific site of action, thereby improving its effectiveness and minimizing side effects. Moreover, nanotechnology has enabled the enhancement of drug solubility, which is crucial for drugs with low water solubility. This development allows such drugs to be more readily absorbed and utilized by the body, leading to better therapeutic outcomes.

Another critical aspect of drug delivery and nanomedicine is the reduction of side effects. Traditional drug administration methods often distribute the medication throughout the body, leading to potential adverse effects on healthy cells and tissues. Nanomedicine offers a more precise approach, selectively delivering drugs to the target area while minimizing damage to healthy cells. This targeted approach can significantly improve patient comfort and overall treatment outcomes. In addition to these technological advancements, drug delivery and nanomedicine also contribute to the broader shift toward patient-centric approaches in healthcare. Patient-centric care emphasizes the importance of understanding and addressing individual patient needs, preferences, and experiences, ultimately aiming to improve patient satisfaction, engagement, and outcomes. This personalized approach to healthcare is increasingly recognized as essential for optimal treatment results.

One way to facilitate patient-centric care in drug delivery and nanomedicine is by integrating customer relationship management (CRM) systems. These systems can help manage patient data, improve communication, and enhance the overall patient experience. By effectively utilizing CRM, healthcare professionals can gain valuable insights into individual patient needs, allowing them to personalize care and optimize treatment plans. CRM systems can also streamline patient interactions, providing real-time access to crucial data and fostering patient engagement. This improved communication can lead to better adherence to treatment plans, which is critical for achieving desired outcomes. Moreover, CRM can help monitor and manage side effects, adjust drug dosages as needed, and track patient responses, ensuring the treatment is tailored to each patient's unique needs and circumstances.

Drug delivery and nanomedicine are transformative fields in modern healthcare that offer numerous benefits, such as targeted drug delivery, improved drug solubility, and reduced side effects. These advancements contribute to the growing emphasis on patient-centric approaches, which seek to address

individual patient needs and preferences. The integration of CRM systems can further enhance these patient-centric approaches, enabling healthcare professionals to deliver personalized care and optimize treatment outcomes. As drug delivery and nanomedicine continue to evolve, their potential to improve healthcare and patient experiences will undoubtedly continue to grow.

5. CRM in Healthcare and its Role in Patient-Centric Care

Customer relationship management (CRM) systems have become an essential component of modern healthcare as they play a pivotal role in fostering patient-centric care. By leveraging CRM technologies, healthcare providers can better manage patient data, enhance communication, and ultimately improve the overall patient experience. In this section, we will delve deeper into the role of CRM in healthcare and how it contributes to personalized care, with a particular focus on the benefits it brings to drug delivery and nanomedicine.

One of the main advantages of utilizing CRM in healthcare is its ability to manage patient data efficiently. With the vast amount of information that healthcare providers must handle, including medical histories, treatment plans, and test results, it is crucial to have a comprehensive and well-organized system in place. CRM systems not only store and manage this data, but they also enable healthcare professionals to quickly and easily access the information when needed. This streamlined access to data allows for more informed decision-making and ensures that patients receive the most appropriate care tailored to their individual needs. In addition to managing patient data, CRM systems also play a crucial role in improving communication between healthcare providers and patients. Effective communication is a cornerstone of patient-centric care, as it helps build trust and rapport, encourages patient engagement, and fosters better adherence to treatment plans. CRM systems facilitate this communication by providing a platform for secure messaging, appointment scheduling, and sharing relevant information, such as test results and educational materials. These tools help keep patients informed and engaged in their care, contributing to more positive outcomes. Another important aspect of CRM in healthcare is its potential to enhance the overall patient experience. By streamlining various processes and interactions, CRM systems can help reduce wait times, minimize administrative burdens, and provide patients with a more seamless and enjoyable healthcare experience. This improved experience can lead to increased patient satisfaction and loyalty, ultimately benefiting both patients and healthcare providers. Personalizing healthcare to meet each patient's unique needs and preferences is a critical aspect of patient-centric care. CRM systems can facilitate this personalization by enabling healthcare providers to understand better and address individual patient needs. Through data analysis and tracking, CRM systems can help identify patterns and trends in patient behavior, preferences, and outcomes, providing valuable insights for healthcare providers to tailor their care accordingly. This personalized approach to care can lead to more effective treatment plans, improved patient engagement, and better overall outcomes.

CRM systems play a vital role in fostering patient-centric care within the healthcare industry, particularly in the realms of drug delivery and nanomedicine. By managing patient data, improving communication, and enhancing the overall patient experience, CRM systems contribute to the personalization of healthcare and the optimization of treatment outcomes. As the healthcare landscape continues to evolve, the importance of CRM systems in supporting patient-centric care will only continue to grow.

6. Applications of CRM in Drug Delivery and Nanomedicine

The applications of CRM in drug delivery and nanomedicine are vast and encompass various aspects of patient care, from monitoring adherence to treatment plans to facilitating personalized drug delivery. In this paragraph, we will examine these specific applications, highlighting the transformative impact that CRM systems can have on the healthcare landscape.

One of the key applications of CRM in drug delivery and nanomedicine is monitoring patient adherence to treatment plans. Ensuring that patients follow their prescribed regimens is crucial for achieving optimal treatment outcomes, as non-adherence can lead to decreased efficacy and increased risk of complications. CRM systems can help healthcare providers track patients' medication usage, appointment attendance, and other adherence-related metrics, allowing them to identify potential issues and intervene when necessary. By closely monitoring patient adherence, healthcare providers can proactively address any concerns and ensure that patients receive the most effective care. Another important application of CRM in drug delivery and nanomedicine is the management of side effects. CRM systems can help healthcare providers track patients' experiences with medications, identifying any adverse reactions or side effects that may occur. By monitoring this information, healthcare providers can adjust drug dosages, switch to alternative medications, or implement other interventions to mitigate the impact of side effects on patients' health and well-being. This proactive side-effect management approach can lead to improved patient outcomes and a better overall experience.

CRM systems can also be instrumental in facilitating personalized drug delivery, an increasingly important aspect of modern healthcare. Personalized drug delivery involves tailoring treatment regimens to individual patients based on factors such as genetic makeup, lifestyle, and disease progression. CRM systems can help healthcare providers track

patient responses to medications, ensuring optimal drug concentrations and minimizing the risk of adverse effects. By analyzing this data, healthcare providers can make informed decisions about dosage adjustments or alternative treatment options, ultimately leading to more effective and personalized care. CRM systems can play a crucial role in identifying potential drug interactions, which can have serious consequences for patients' health. With access to comprehensive patient data, healthcare providers can use CRM systems to analyze medication usage and identify combinations that may pose a risk. By flagging potential interactions, CRM systems can help healthcare providers take proactive steps to prevent adverse effects and ensure patient safety.

The applications of CRM in drug delivery and nanomedicine are diverse and far-reaching, with the potential to significantly impact patient care and outcomes. By monitoring patient adherence, managing side effects, and facilitating personalized drug delivery, CRM systems can help healthcare providers deliver more effective and patient-centric care. As drug delivery and nanomedicine continue to evolve, CRM systems' role in optimizing treatment outcomes will become increasingly important, highlighting the need for continued investment and innovation in this area.

7. Challenges and Opportunities in Integrating CRM into Drug Delivery and Nanomedicine

Integrating CRM into drug delivery and nanomedicine presents both challenges and opportunities for the healthcare industry. In this paragraph, we will examine the various hurdles that must be overcome in order to successfully implement CRM systems in these fields, as well as the potential benefits that can be achieved through their successful integration.

One of the primary challenges associated with integrating CRM into drug delivery and nanomedicine is ensuring data privacy and security. With the vast amounts of sensitive patient information stored in CRM systems, healthcare providers must implement robust measures to protect this data from unauthorized access and breaches. This requires significant investment in cybersecurity infrastructure, staff training, and ongoing monitoring to maintain the integrity and confidentiality of patient information. Additionally, healthcare providers must navigate complex regulatory environments that govern data protection, further complicating the process of integrating CRM systems.

Another challenge in integrating CRM into drug delivery and nanomedicine is achieving interoperability among various healthcare systems and technologies. For CRM systems to be effective, they must be able to communicate seamlessly with electronic health records, laboratory systems, and other healthcare technologies. This necessitates the development of standardized data formats, protocols, and interfaces that facilitate interoperability, as well as the investment in system upgrades and modifications to ensure compatibility. The successful integration of CRM into drug delivery and nanomedicine requires healthcare professionals to adapt to new technologies and workflows. This may involve retraining staff members, redesigning processes, and overcoming resistance to change, which can be time-consuming and resource-intensive. Healthcare providers must be committed to fostering a culture of continuous learning and improvement to facilitate the adoption of CRM systems and maximize their potential benefits.

Despite these challenges, significant opportunities are associated with integrating CRM into drug delivery and nanomedicine. One such opportunity is the potential for improved patient outcomes, as CRM systems enable healthcare providers to deliver more personalized and effective care. By streamlining processes, enhancing communication, and providing real-time access to patient data, CRM systems can help providers make more informed decisions and ultimately improve the quality of care delivered. Integrating CRM into drug delivery and nanomedicine can lead to cost savings for healthcare providers. More efficient processes and better-informed decision-making can result in reduced waste and lower overall healthcare costs. CRM systems can help healthcare organizations operate more effectively and sustainably by optimizing resource allocation and eliminating inefficiencies.

The integration of CRM into drug delivery and nanomedicine presents both challenges and opportunities for the healthcare industry. While issues related to data privacy, interoperability, and staff adaptation must be addressed, the potential benefits of improved patient outcomes, cost savings, and streamlined processes make the integration of CRM into these fields a compelling prospect. By overcoming these hurdles and capitalizing on the opportunities, healthcare providers can harness the power of CRM systems to revolutionize drug delivery and nanomedicine, ultimately leading to a more efficient and effective healthcare system.

8. Conclusion and Future Directions

Customer relationship management (CRM) systems hold great potential in enhancing patient-centric approaches within drug delivery and nanomedicine, ultimately contributing to more effective and personalized healthcare. By streamlining processes, improving communication, and providing real-time access to patient data, CRM systems can facilitate the development of targeted drug delivery systems, better manage side effects, and optimize drug dosages according to individual patient needs. In order to fully realize the benefits of CRM in these fields, continued research, development, and integration of new technologies are essential.

The integration of CRM into drug delivery and nanomedicine is not without its challenges, such as ensuring data privacy and security, achieving interoperability among various healthcare systems, and encouraging healthcare professionals to adapt to new technologies. However, overcoming these hurdles can lead to significant opportunities in the form of improved patient outcomes, cost savings, and more efficient healthcare processes. As the healthcare industry continues to evolve, embracing patient-centric care and personalized medicine will become increasingly important in meeting the diverse needs of patients.

Future directions for integrating CRM into drug delivery and nanomedicine should focus on leveraging emerging technologies, such as artificial intelligence (AI) and machine learning (ML). By incorporating these advanced tools, CRM systems can further enhance patient care and optimize drug delivery. AI and ML algorithms have the potential to analyze large datasets, identify patterns, and make predictions that can help healthcare providers make more informed decisions, improve treatment plans, and anticipate potential complications.

The integration of AI and ML into CRM systems can facilitate the development of more precise and targeted drug delivery systems. For instance, AI-driven algorithms can help predict patient responses to specific medications, enabling healthcare providers to customize treatment regimens and ensure optimal drug concentrations. Furthermore, ML can be employed to analyze patterns in patient adherence to treatment plans, thereby identifying factors contributing to non-adherence and enabling providers to develop targeted interventions.

As the fields of drug delivery and nanomedicine continue to advance, the integration of CRM systems and emerging technologies, such as AI and ML, will play a crucial role in shaping the future of healthcare. By focusing on patient-centric approaches and leveraging the power of these tools, healthcare providers can revolutionize drug delivery, minimize adverse side effects, and provide more personalized patient care. In doing so, the healthcare industry can make strides toward achieving better patient outcomes, reducing healthcare costs, and enhancing the overall patient experience.

The integration of CRM into drug delivery and nanomedicine has the potential to transform healthcare and contribute to a more patient-centric approach to care. Continued research and development, as well as the incorporation of emerging technologies like AI and ML, will be essential to unlocking the full potential of CRM systems and ensuring that patients receive the most effective and personalized care possible. The future of drug delivery and nanomedicine will undoubtedly be shaped by the ongoing pursuit of innovative, patient-centric solutions driven by CRM and other cutting-edge technologies.

References

[1] Theresa M. Allen, and Pieter R. Cullis, “Liposomal Drug Delivery Systems: From Concept to Clinical Applications,” *Advanced Drug Delivery Reviews*, vol. 65, no. 1, pp. 36-48, 2013. [CrossRef] [Google Scholar] [Publisher Link]

[2] W. Bains, and B. Rattigan, “The Role of CRM in Healthcare: A Review of the Literature,” *Health Marketing Quarterly*, vol. 34, no. 1, pp. 1-20, 2017.

[3] Irène Brigger, Catherine Dubernet, and Patrick Couvreur, “Nanoparticles in Cancer Therapy and Diagnosis,” *Advanced Drug Delivery Reviews*, vol. 64, pp. 24-36, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[4] L. Chan, and N. Mitra, “Nanomedicine: Promises and Challenges for the Future of Public Health,” *International Journal of Nanomedicine*, vol. 11, pp. 4831-4845, 2016.

[5] K. Chaturvedi, Ganguly, and M. N. Nadagouda, “Carbon Nanotubes: A Review on Structure and Their Interaction with Proteins,” *Journal of Biomedical Science*, vol. 20, no. 1, 2013.

[6] Fabienne Danhier et al., “PLGA-Based Nanoparticles: An Overview of Biomedical Applications,” *Journal of Controlled Release*, vol. 161, no. 2, pp. 505-522, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[7] P. Deshpande, A. Jhaveri, and V. Patravale, “Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Emerging Lipid-Based Drug Delivery Systems,” *Expert Opinion on Drug Delivery*, vol. 9, no. 3, pp. 325-341, 2012.

[8] Can Dincer et al., “Multiplexed Point-Of-Care Testing – xPOCT,” *Trends in Biotechnology*, 35(8), 728-742. [CrossRef] [Google Scholar] [Publisher Link]

[9] Owen S. Fenton et al., “Advances in Biomaterials for Drug Delivery,” *Advanced Materials*, vol. 30, no. 29, 2018. [CrossRef] [Google Scholar] [Publisher Link]

[10] N. K. Garg et al., “Advanced Targeted Drug Delivery Approaches for the Management of Cancer: A Comprehensive Review,” *Drug Delivery and Translational Research*, vol. 7, no. 2, pp. 214-235, 2017.

[11] GBD, “Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990-2016: a Systematic Analysis for the Global Burden of Disease Study 2016,” *Lancet*, vol. 390, no. 10100, pp. 1211-1259, 2017. [CrossRef] [Google Scholar] [Publisher Link]

[12] Suresh Vundavalli et al., "Biodegradable Super Absorbent Nano Polymer: Properties and its Applications," *SSRG International Journal of Agriculture & Environmental Science*, vol. 7, no. 6, pp. 59-71, 2020. [CrossRef] [Google Scholar] [Publisher Link]

[13] Jeffrey Hrkach et al., "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile," *Science Translational Medicine*, vol. 4, no. 128, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[14] K. K. Jain, "Nanomedicine: Application of Nanobiotechnology in Medical Practice," *Medical Principles and Practice*, vol. 17, no. 2, pp. 89-101, 2012. [CrossRef] [Google Scholar] [Publisher Link]

[15] Piotr Kozarewicz, "Regulatory Perspectives on Acceptability Testing of Dosage Forms in Children," *International Journal of Pharmaceutics*, vol. 469, no. 2, pp. 245-248, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[16] Betty Y. S. Kim et al., "Nanomedicine," *New England Journal of Medicine*, vol. 363, no. 25, pp. 2434-2443, 2010. [CrossRef] [Google Scholar] [Publisher Link]

[17] Robert Langer, "Biomaterials in Drug Delivery and Tissue Engineering: One Laboratory's Experience," *Accounts of Chemical Research*, vol. 33, no. 2, pp. 94-101, 2000. [CrossRef] [Google Scholar] [Publisher Link]

[18] James F Leary, and Jaehong Key, "Nanoparticles for Multimodal in Vivo Imaging in Nanomedicine," *International Journal of Nanomedicine*, vol. 9, pp. 711-726, 2014. [CrossRef] [Google Scholar] [Publisher Link]

[19] Vincent H.L. Lee, and Akira Yamamoto, "Penetration and Enzymatic Barriers to Peptide and Protein Absorption," *Advanced Drug Delivery Reviews*, vol. 4, no. 2, pp. 171-207, 1989. [CrossRef] [Google Scholar] [Publisher Link]

[20] N. N. Mahmoud, "The Impact of CRM on Patient Adherence to Treatment Plans: A Review of the Literature," *Journal of Health and Social Sciences*, vol. 3, no. 3, pp. 341-356, 2018.

[21] Simona Mura, Julien Nicolas, and Patrick Couvreur, "Stimuli-Responsive Nanocarriers for Drug Delivery," *Nature Materials*, vol. 12, no. 11, pp. 991-1003, 2013. [CrossRef] [Google Scholar] [Publisher Link]

[22] Dan Peer, "Nanocarriers as an Emerging Platform for Cancer Therapy," *Nature Nanotechnology*, vol. 2, no. 12, pp. 751-760, 2017. [CrossRef] [Google Scholar] [Publisher Link]

[23] Mihail C. Roco, "The Long View of Nanotechnology Development: The National Nanotechnology Initiative at 10 years," *Journal of Nanoparticle Research*, vol. 13, no. 2, pp. 427-445, 2011. [CrossRef] [Google Scholar] [Publisher Link]

[24] Komarala Narendra Babu et al., "An Updated Review on Nanoparticles Targeting Prostate Cancer," *SSRG International Journal of Medical Science*, vol. 9, no. 6, pp. 18-31, 2022. [CrossRef] [Publisher Link]

[25] T. Schultz, and R. Desbordes, "The Role of Customer Relationship Management in the Pharmaceutical Industry: A Review," *Health Policy and Technology*, vol. 6, no. 1, pp. 1-10, 2017.

[26] Rajesh Singh, and James W. Lillard, "Nanoparticle-Based Targeted Drug Delivery," *Experimental and Molecular Pathology*, vol. 86, no. 3, pp. 215-223, 2009. [CrossRef] [Google Scholar] [Publisher Link]

[27] Vladimir P. Torchilin, "Recent Advances with Liposomes as Pharmaceutical Carriers," *Nature Reviews Drug Discovery*, vol. 4, no. 2, pp. 145-160, 2005. [CrossRef] [Google Scholar] [Publisher Link]

[28] Kathryn E. Uhrich et al., "Polymeric Systems for Controlled Drug Release," *Chemical Reviews*, vol. 99, no. 11, pp. 3181-3198, 1999. [CrossRef] [Google Scholar] [Publisher Link]

[29] C. Lee Ventola, "The Nanomedicine Revolution: Part 1: Emerging concepts," *Pharmacy and Therapeutics*, vol. 37, no. 9, pp. 512-525, 2012. [Google Scholar] [Publisher Link]

[30] Volker Wagner et al., "The Emerging Nanomedicine Landscape," *Nature Biotechnology*, vol. 24, no. 10, pp. 1211-1217, 2006. [CrossRef] [Google Scholar] [Publisher Link]

[31] D. M. West, "The Promise and Peril of Electronic Health Records," *Science and Technology*, vol. 27, no. 4, pp. 63-70, 2011.

[32] George M Whitesides, "The 'Right' size in Nanobiotechnology," *Nature Biotechnology*, vol. 21, no. 10, pp. 1161-1165, 2003. [CrossRef] [Google Scholar] [Publisher Link]

[33] M. T. Halpern, and M. A. Romaire, "Use of Electronic Medical Records in Oncology Outcomes Research," *Clinical Outcomes Research*, vol. 6, pp. 1-15, 2014.

[34] Sanjeeb K. Sahoo, and Vinod Labhasetwar, "Nanotech Approaches to Drug Delivery and Imaging," *Drug Discovery Today*, vol. 8, no. 24, pp. 1112-1120. [CrossRef] [Google Scholar] [Publisher Link]